Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis

Susanne Gaul, Aleksandra Leszczynska, Fernando Alegre, +15

Journal of Hepatology

Liver FibrosisStellate Cell ActivationImmunologyPathologyCell Death +15

Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells

Alberto Martí-Rodrigo, Fernando Alegre, Ángela B. Moragrega, +7

Gut

ER stress in human hepatic cells treated with Efavirenz: Mitochondria again

Nadezda Apostolova, Leysa J. Gómez-Sucerquia, Fernando Alegre, +5

Journal of Hepatology

InflammationHepatologyMitochondrial FunctionLiver PhysiologyPathology +9

Neuronal Bioenergetics and Acute Mitochondrial Dysfunction: A Clue to Understanding the Central Nervous System Side Effects of Efavirenz

Haryes A. Funes, Nadezda Apostolova, Fernando Alegre, +4

The Journal of Infectious Diseases

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

Ana Blas‐García, Miriam Polo, Fernando Alegre, +4

Journal of Antimicrobial Chemotherapy

Role of p62/SQSTM1 beyond autophagy: a lesson learned from drug‐induced toxicity <i>in vitro</i>

Fernando Alegre, Ángela B. Moragrega, Miriam Polo, +4

British Journal of Pharmacology

Involvement of Nitric Oxide in the Mitochondrial Action of Efavirenz: A Differential Effect on Neurons and Glial Cells

Nadezda Apostolova, Haryes A. Funes, Ana Blas‐García, +3

The Journal of Infectious Diseases

Drug EfavirenzMitochondrial DysfunctionNitric OxideImmunologyCell Death +22

Lon protease: a novel mitochondrial matrix protein in the interconnection between drug‐induced mitochondrial dysfunction and endoplasmic reticulum stress

Miriam Polo, Fernando Alegre, Ángela B. Moragrega, +5

British Journal of Pharmacology

Mitochondrial (dys)function – a factor underlying the variability of efavirenz‐induced hepatotoxicity?

Miriam Polo, Fernando Alegre, Haryes A. Funes, +4

British Journal of Pharmacology

A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma

Fernando Alegre, Amanda R. Ormonde, Kellie M. Snider, +3

PLoS ONE

Tumor BiologyMature Mir-34aMicrorna-34a ProdrugHuman Osa ModelsMedicine +12